Kenneth D Cain and Sudheesh Ponnerassery
Transcript of Kenneth D Cain and Sudheesh Ponnerassery
![Page 1: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/1.jpg)
Kenneth D Cain and Sudheesh Ponnerassery
Department of Fish & Wildlife Sciences and the Aquaculture Research Institute, University of Idaho, 875 Perimeter Drive MS1136, Moscow, ID 83844-1136
Email: [email protected]
LSRCP meetingMarch 10-12, 2015Lewiston, Idaho
![Page 2: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/2.jpg)
Outline
1. Coldwater disease (CWD)2. Vaccine Development
1. Initial (B.17) vaccine2. “Newer” (FP-B.17-ILM) vaccine
3. Research • Study 1 (Coho salmon)• Study 2 (Immersion delivery duration)• Study 3 (Size at vaccination)• Study 4 (Dose, booster, and duration
of protection)4. Field trials5. Summary/Conclusions
![Page 3: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/3.jpg)
Coldwater Disease (CWD)/Rainbow trout fry syndrome (RTFS)
• Number 1 disease problem for US trout Industry• Global problem in salmonid aquaculture • Causes greater mortality for US public salmon/trout
aquaculture than any other disease
![Page 4: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/4.jpg)
Coldwater Disease (CWD)/Rainbow trout fry syndrome (RTFS)
Steelhead
Steelhead
Yellow pigmented bacteria
![Page 5: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/5.jpg)
CWD/RTFS vaccine: University of Idaho lab – over 15 years of
effort – Many experimental CWD vaccines – Limited success via immersion delivery
Shifted focus - Live attenuated vaccine – Stimulate both innate and adaptive immune
responses– Three live fish vaccines approved and
commercialized
Initial live attenuated F. psychrophilum (B.17) vaccine developed (LaFrentz et al., 2008)
Enhanced “new” live FP-B.17-ILM vaccine developed (Long et al., 2013) Producing in Iron Limited Media
Vaccine Development
![Page 6: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/6.jpg)
Results of the early “initial” B.17 testing: Vaccine is safe (field/lab) Some inconsistencies with field and lab immersion
vaccination trials Reports/data submitted to USDA
- Only outstanding requirement – serial safety testing at USDA licensed facility
Could improvements be made? Can B.17 vaccine be enhanced to provide greater
protection/immunity when delivered by immersion? Iron-limited media (ILM)
Attenuated Vaccine
![Page 7: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/7.jpg)
Study 1 (FP-B.17-ILM) vs initial (B.17) vaccine)
Initial immunization
(immersion and injection)
Booster immunization
Injection challenge
Serum collection(0 - 12 weeks: Ab
titers)
0 weeks 4 weeks post-immunization
6 weeks post-immunization
Experimental design:- Coho salmon (3.6g)- 1 x 107- 108 cfu/ml- adipose fin clip incorporated for immersion treatment- Injection vaccination or 1 hour immersion (B.17 or ILM vaccine)
![Page 8: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/8.jpg)
Results: Antibody titers (Coho salmon)
Note – fish were injection challenged with Fp 259‐93 at 6 weeks
Fp Challenge Fp Challenge
![Page 9: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/9.jpg)
Coho salmon vaccine trial results Vaccine Delivery Method
Treatment CPM ± SEMRelativepercent survival
Injection
Mock Immunized 65.3 ± 10.4a
B.17 6.7 ± 3.5b 90
ILM vaccine 1.3 ± 1.3b 98
Immersion
Mock Immunized 54 ± 2a
B.17 29.3 ± 10.7a,b 46
ILM vaccine 14.7 ± 6.7b 73
Note – adipose fin removed just prior to immersion delivery of vaccine
![Page 10: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/10.jpg)
Study 2 (FP-B.17-ILM optimization): Delivery duration for immersion vaccination
Initial immunization (immersion)
Booster immunization(immersion)
Injection challenge
Serum collection(0 - 8 weeks: Ab titers)
0 week 2 weeks post-immunization
8 weeks post-immunization
Experimental design• Rainbow trout: mean size 2.6 g• FP-B.17-ILM initial vaccination dose : 5.0 X 1010 cfu ml-1• Booster dose: 4.0 X 1010 cfu ml-1• 1.5 min, 3 min, 6 min, 30 min immersion
![Page 11: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/11.jpg)
Duration of vaccine delivery - antibody titers2 wk 4 wk
6 wk 8 wk
* ** *
* **
*
* * * * * * * *
![Page 12: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/12.jpg)
At time point when CPM reached60% in control groups
At the end of 28 days challenge
* ** * *
*
Cumulative Percent Mortality (CPM)CPM 60% Final CPM 28 days
![Page 13: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/13.jpg)
Challenge dose of virulent F. psychrophilum (cfu fish-1) = 1.46 x 107
Treatments Fish/ treatment RPS (%)
30 min vaccinated 25 fish x 3 tanks 52
6 min vaccinated 25 fish x 3 tanks 53
3 min vaccinated 25 fish x 3 tanks 47
1.5 min vaccinated 25 fish x 3 tanks 36
28 day relative percent survival (RPS)
![Page 14: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/14.jpg)
Study 3: FP-B.17-ILM testing (size at vaccination)
Initial immunization (immersion)
Booster immunization(immersion)
Injection challenge
Serum collection(0 - 8 weeks: Ab titers)
0 weeks2 weeks post-immunization
8 weeks post-immunization
Experimental design:• Rainbow trout: 0.5 g, 1.0 g, 2.0 g: 150 fish/ group• FP-B.17-ILM initial vaccination dose: 9.0 X 1010 cfu ml-1• Booster dose: 7.0 X 1010 cfu ml-1• 3 min immersion
![Page 15: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/15.jpg)
Size at vaccination - antibody titers2 wk 4 wk
6 wk 8 wk
*
*
* **
* * *
** *
![Page 16: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/16.jpg)
Cumulative Percent Mortality (CPM)
At time point when CPM reached60% in control groups
At the end of 28 days challenge
**
* * **
CPM 60% Final CPM 28 days
![Page 17: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/17.jpg)
28 day relative percent survival (RPS)
Treatments Challenge dose (cfu fish-1)
Fish/ treatment RPS (%)
2 g-ILM 5.18 x 107 25 fish x 3 tanks 60
1 g-ILM 3.45 x 107 25 fish x 3 tanks 59
0.5 g-ILM 1.73 x 107 25 fish x 3 tanks 55
![Page 18: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/18.jpg)
Study 4: FP-B.17-ILM dose optimization and duration of protection
Initial immunization (immersion)
With or w/o Booster
immunization(immersion)
Injection challenge
Serum collection(0 - 24 weeks: Ab titers)
0 weeks2 weeks post-immunization
8, 12, 24 weeks post-immunization
Experimental design:• Rainbow trout: 2.6 g: 3 min immersion• FP-B.17-ILM initial vaccination dose : ODs: 0.04, 0.08, 0.15, and 0.3:
(2.50 X 105 cfu ml-1 to 1.58 x 1010 cfu ml-1): challenge @ 8,12,24 wks)• One, two, or no booster vaccination (challenge at 8 and 12 weeks)
![Page 19: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/19.jpg)
Dose and duration of protection (antibody titers)
![Page 20: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/20.jpg)
At time point when CPM reached60% in control groups
At the end of 28 days challenge
Cumulative Percent Mortality (CPM @ 8 wks)
![Page 21: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/21.jpg)
At time point when CPM reached60% in control groups
At the end of 28 days challenge
Cumulative Percent Mortality (CPM @ 12 wks)
a a aa
a
![Page 22: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/22.jpg)
28 day relative percent survival (RPS)
Treatment groups Initial vaccination
dose (cfu ml-1)
RPS (%)
Week 8 Week 12 Week 24
OD 0.3-B.17-ILM 1.58 X 1010 67 61 70
OD 0.15-B.17-ILM 3.00 X 108 40 48 55
OD 0.08-B.17-ILM 1.00 X 106 35 43 36
OD 0.04-B.17-ILM 2.50 X 105 29 45 34
![Page 23: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/23.jpg)
28 day relative percent survival (RPS)
Treatments Initial vaccination
dose (cfu ml-1)
RPS (%)
Week 8 Week 12
One booster-
0.3-B.17-ILM 1.58 X 1010 67 61
Two booster-
0.3-B.17-ILM 1.58 X 101056 48
No booster-
0.3-B.17-ILM 1.58 X 101017 13
![Page 24: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/24.jpg)
Field trial – ILM vaccine at Magic Springs hatchery
Initial immunization (immersion)
Booster immunization
Outside (duplicate) raceways)
0 weeks 2 weeks post-immunization
Monitor for diseases/mortality
Experimental design:• Rainbow trout (~ 1.5g): ~ 50,000 controls/50,000 vaccinates• Primary - 3 L (bottles) vaccine (8 passes/bottle @ 10lbs/pass)• Boosted @ 2 weeks (6 bottles vaccine)• 3 min immersion
![Page 25: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/25.jpg)
Field trial – ILM vaccine at Magic Springs hatchery
Jerry Zinn!! TomJerry
Gary
![Page 26: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/26.jpg)
Field trial – ILM vaccine at Magic Springs hatchery
![Page 27: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/27.jpg)
Treatment groups
ELIS
A tit
er
V2 C2
0
200
400
600
800
Field trial – Antibody response following vaccination with ILM vaccine
3 wks (7/2/14) 7 wks (8/4/14)
Treatment groups
ELIS
A tit
er
V10/12
C03/09
0
2000
4000
6000
8000
![Page 28: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/28.jpg)
0
50
100
150
200
250
300
14 16 18 20 22 24 26 28 30 1 3 5 7 9 11 13 15 17 19
ControlsVaccinates
CWD vaccine field trial – Magic Springs
(60 days post vaccination)
Initial control population at ponding = 46,948 (raceways 3,9)Initial vaccinate population at ponding = 50,529 (raceways 10,12)
Day
Dai
ly m
orta
lity
![Page 29: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/29.jpg)
CWD vaccine field trial – Magic Springs
![Page 30: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/30.jpg)
CWD vaccine field trial – Magic Springs
![Page 31: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/31.jpg)
CWD vaccine field trial – Magic Springs
![Page 32: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/32.jpg)
CWD vaccine field trial – Magic Springs(Clinical exam of fish)
7/31/14 Slight increase in mortality in controls 6 control; 6 vaccinates sampled (TYES plates for
bacterial isolation) Confirmed F. psychrophilum (2/6 controls)
8/13/14 Increasing daily mortality in controls (significant lesions
present) 12 controls; 12 vaccinates sampled
![Page 33: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/33.jpg)
CWD vaccine field trial – Magic Springs(Clinical exam of fish)
Clinical exam results (8/13/14)Controls EBI/BGD 9/12 fish positive for IHNV F. psychrophilum confirmed
(FAT and PCR) - only 1 fishVaccinates Minor BGD
(limited signs or bacterial growth) No virus F. psychrophilum confirmed
Only 1 fish
![Page 34: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/34.jpg)
Second Magic Springs trialAntibody responses
Treatment groups
ELI
SA
tite
r
V C
0
500
1000
1500
2000
Treatment groups
ELI
SA
tite
r
V C
0
10000
20000
30000
Wk- 4, 11/13/2014 Wk-9, 12/18/2014
![Page 35: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/35.jpg)
American Falls (IDFG) trialAntibody responses
Treatment groups
ELIS
A ti
ter
Vaccin
ated
Control
0
500
1000
1500
2000Sample Titer Sample TiterV1 0 C1 0V2 0 C2 0V3 0 C3 0V4 0 C4 0V5 0 C5 0V6 0 C6 0V7 0 C7 0V8 0 C8 0V9 0 C9 0V10 50 C10 0V11 0 C11 0V12 50 C12 0V13 0 C13 0V14 0 C14 0V15 0 C15 0
12/22/2014
![Page 36: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/36.jpg)
Second Magic Springs and American Falls (IDFG) trial
Inconclusive field trial results Magic Springs – Fish responded to vaccine and produced
strong antibody response No CWD outbreak
American Falls – Fish did not respond to vaccine (no antibodies) – something went wrong Primary and booster vaccination?
Consistency between all vaccinations (lab and all field trials)? Was there an issue with viability of attenuated strain?
Time of vaccination following thawing? Inconsistent production at UI (not under strict quality control)?
All vaccination bottles checked prior to storage.
![Page 37: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/37.jpg)
SummaryFP-B.17-ILM vaccine optimization work (lab):
Vaccine protects Coho salmon and rainbow trout via immersion delivery
Immersion delivery of 3.0 min or greater provides solid protection
Vaccine protects fish as small as 0.5 g Level of protection is dose dependent One booster immunization is required Significant protection (high RPS) lasts for at least 24
weeks post vaccination
![Page 38: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/38.jpg)
SummaryField trials:
Initial field trial (Magic Springs) demonstrated safety and efficacy – even in presence of mixed infection
Second field trial (Magic Springs) demonstrated safety and strong immune response – no CWD outbreak so - no protection data
American Falls trial – Fish never developed an immune response Some aspect of vaccination did not work Need to determine factor(s) caused this and optimize
protocols for vaccine administration and/or production and storage
![Page 39: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/39.jpg)
What’s left to do?Live attenuated FP-B.17-ILM vaccine:
Vaccine production - practical large scale growth, manufacturing and storage characteristics
Complete optimization work Safety/efficacy trials (USDA approval)
Laboratory and field safety trials on manufactured product
Conditional/Full licensing Marketing and sales
This vaccine shows strong efficacy via immersion delivery and once optimized will be an important tool for managing CWD at salmonid hatcheries.
![Page 40: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/40.jpg)
Acknowledgments
Collaborators• CSF, Scott LaPatra• WSU, Doug Call/Devendra Shah, Graduate students: • Ben LaFrentz, Amy Long, Tarah Johnson, Nicole
Lindstrom, David Burbank, Tyson Fehringer, Mark Polinski
Undergraduate Students: • Kurt Eversman, Matt Albert, Kali Turner, etc.
Lab SupportNajeeb Parvez
Funding• Idaho Department of Commerce - IGEM• Idaho State Board of Education – HERC• Western Regional Aquaculture Center (USDA)• WSU /UI Aquaculture Initiative (USDA)• USDA/SBIR I&II
![Page 41: Kenneth D Cain and Sudheesh Ponnerassery](https://reader031.fdocuments.us/reader031/viewer/2022022516/6217bbdbc8a3981b5f014822/html5/thumbnails/41.jpg)
Questions?